Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMZAL7W)

Drug Name
Promazine Drug Info
Synonyms
Ampazine; Berophen; Esparin; Liranol; Prazin; Prazine; Promazin; Promazina; Promazinum; Promwill; Propazinum; Protactyl; Romtiazin; Sinophenin; Tomil; Verophen; Combelen [veterinary]; Promazina [Italian]; A 145; RP 3276; WY 1094; Combelen [veterinary] (TN); Neo-Hibernex; Promazina [INN-Spanish]; Promazine (INN); Promazine [INN:BAN]; Promazinum [INN-Latin]; Sparine (TN); Wy-1094; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; Dimethyl(3-phenothiazin-10-ylpropyl)amine; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-(3-(Dimethylamino)propyl)phenothiazine; 10-[3-(Dimethylamino)propyl]phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-(9CI); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride
Therapeutic ClassAntipsychotic Agents
Cross-matching ID
PubChem CID
4926
ChEBI ID
CHEMBL564
CAS Number
CAS 58-40-2
TTD Drug ID
D00NAX
VARIDT Drug ID
DR00887
INTEDE Drug ID
DR1351

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.57 0.00e+0 19/20 (95%) MSMO1;SQLE;DHCR24;...
Terpenoid backbone biosynthesis 2.17 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;ACAT2;...
PPAR signaling pathway 2.03 6.48e-3 66/74 (89.19%) HMGCS1;SCD;FADS2;...
mTOR signaling pathway 1.95 1.22e-2 114/154 (74.03%) LPIN1;SGK1;DDIT4;...
Biosynthesis of unsaturated fatty acids 1.92 1.36e-2 21/27 (77.78%) SCD;FADS1;FADS2;...
Melanogenesis 1.87 2.11e-2 74/101 (73.27%) CALML5;TYRP1;PLCB1;...
Gap junction 1.84 2.78e-2 72/88 (81.82%) TUBA1A;PDGFD;PLCB1;...
Wnt signaling pathway 1.84 2.43e-2 124/166 (74.7%) PPP3CA;LGR5;LGR4;...
Lysosome 1.79 3.03e-2 115/128 (89.84%) NPC1;NEU1;MCOLN1;...
Cholesterol metabolism 1.79 3.11e-2 44/50 (88%) LDLR;CD36;NPC1;...
Selenocompound metabolism 1.78 3.18e-2 11/17 (64.71%) PAPSS2;SEPHS1;PAPSS1;...
Aldosterone synthesis and secretion 1.78 3.08e-2 85/98 (86.73%) LDLR;CALML5;PLCB1;...
Nitrogen metabolism -1.67 2.34e-2 16/17 (94.12%) CA7;CA14;CA8;...
Collecting duct acid secretion -1.68 2.22e-2 22/27 (81.48%) SLC4A1;ATP6V1B1;ATP6V1F;...
Mineral absorption -1.69 2.22e-2 48/60 (80%) MT1HL1;SLC26A3;HMOX1;...
RIG-I-like receptor signaling pathway -1.71 1.88e-2 64/70 (91.43%) MAPK8;DHX58;MAPK11;...
Leishmaniasis -1.71 1.96e-2 67/77 (87.01%) MAPK13;FCGR3B;HLA-DOB;...
Leukocyte transendothelial migration -1.71 2.03e-2 90/114 (78.95%) CTNNB1;MAPK11;CTNNA3;...
Allograft rejection -1.71 2.12e-2 32/38 (84.21%) HLA-DQB1;HLA-C;HLA-A;...
Coronavirus disease -1.73 1.89e-2 215/232 (92.67%) IFNAR1;RPS15A;IFNA14;...
Glycine, serine and threonine metabolism -1.73 1.98e-2 31/40 (77.5%) DAO;ALAS2;SHMT1;...
Thermogenesis -1.74 1.98e-2 173/232 (74.57%) NDUFB1;NDUFS1;MAPK13;...
TNF signaling pathway -1.74 2.07e-2 103/112 (91.96%) CHUK;CSF1;MAPK13;...
Autoimmune thyroid disease -1.75 2.02e-2 46/53 (86.79%) CTLA4;HLA-DQB1;IFNA7;...
Nucleotide excision repair -1.77 1.79e-2 40/47 (85.11%) RPA1;GTF2H5;GTF2H3;...
Spliceosome -1.78 1.71e-2 101/150 (67.33%) FUS;PPIH;SNRNP200;...
Systemic lupus erythematosus -1.79 1.62e-2 45/135 (33.33%) HLA-DQB1;CTSG;CD28;...
One carbon pool by folate -1.85 6.22e-3 15/20 (75%) SHMT1;ATIC;ALDH1L1;...
Chagas disease -1.85 6.67e-3 93/102 (91.18%) MAPK14;MAPK10;PPP2R1B;...
Rheumatoid arthritis -1.87 5.59e-3 78/93 (83.87%) CSF1;ATP6V1G1;HLA-DOB;...
Prion disease -1.87 6.05e-3 209/273 (76.56%) NDUFB1;NDUFS1;MAPK13;...
Ribosome biogenesis in eukaryotes -1.91 4.72e-3 52/108 (48.15%) GAR1;CSNK2B;NOP56;...
Graft-versus-host disease -1.91 5.19e-3 32/42 (76.19%) KIR2DL1;HLA-DQB1;HLA-C;...
RNA polymerase -1.91 5.76e-3 23/31 (74.19%) POLR2K;POLR2I;POLR3K;...
Huntington disease -1.92 6.48e-3 233/306 (76.14%) PSMC5;NDUFS8;POLR2K;...
Non-alcoholic fatty liver disease -1.93 7.41e-3 126/155 (81.29%) COX7B;NDUFS2;NDUFB1;...
Citrate cycle (TCA cycle) -1.93 6.92e-3 30/30 (100%) SDHA;IDH2;FH;...
Parkinson disease -1.96 8.30e-3 176/249 (70.68%) ATP5F1D;COX7A2L;BAX;...
Legionellosis -1.97 7.78e-3 51/57 (89.47%) NFKB2;CASP8;NAIP;...
Type I diabetes mellitus -1.99 6.92e-3 38/43 (88.37%) HLA-DQB1;HLA-C;PTPRN2;...
Oxidative phosphorylation -2.26 0.00e+0 93/133 (69.92%) COX7B;NDUFS2;NDUFB1;...
Ribosome -2.50 0.00e+0 113/158 (71.52%) RPS15A;RPS18;RPL19;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 10uM 6H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 10uM 6H
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 10uM 6H
MDST8 CVCL_1400 Homo sapiens 10uM 6H
NCI-H508 CVCL_1561 Homo sapiens 10uM 6H
SNU-1040 CVCL_5001 Homo sapiens 10uM 6H
SNU-C4 CVCL_5008 Homo sapiens 10uM 6H
SNU-C5 CVCL_5009 Homo sapiens 10uM 6H
SW480 CVCL_0546 Homo sapiens 10uM 6H
SW620 CVCL_0547 Homo sapiens 10uM 6H
SW948 CVCL_0550 Homo sapiens 10uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 10uM 6H
HT115 CVCL_1294 Homo sapiens 10uM 6H
RKO CVCL_0504 Homo sapiens 10uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 10uM 6H
SNG-M CVCL_1707 Homo sapiens 10uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 10uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 10uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 10uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 10uM 6H
T3M-10 CVCL_1729 Homo sapiens 10uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 10uM 6H
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 10uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 10uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 10uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 10uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 10uM 6H
OV7 CVCL_1623 Homo sapiens 10uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 10uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 10uM 6H
RMUG-S CVCL_1666 Homo sapiens 10uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 10uM 6H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 10uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 10uM 6H
PL-21 CVCL_2161 Homo sapiens 10uM 6H
SKM-1 CVCL_0010 Homo sapiens 10uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 10uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 10uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 10uM 6H